In 2026, Provigil (modafinil) continues to be the premier FDA-approved wakefulness-promoting agent for treating excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. Unlike traditional stimulants that act broadly on the nervous system, Provigil targets the brain’s sleep-wake centers more selectively, modulating neurotransmitters like dopamine and orexin to provide a "clean" alertness. This allows users to stay awake and focused for a sustained 10-to-12-hour window without the extreme "crash" or physical jitters typically associated with caffeine or amphetamines.